July 24, 2018
The arrival of a new class of nucleic acid medicines called siRNA therapeutics is drawing near, with Alnylam Pharmaceuticals’ hereditary ATTR amyloidosis treatment patisiran likely to be the first to clinch approval as early as this summer. Although the drug...read more